Professor of Medicine, University Washington; Member, Fred Hutchinson Cancer Research Center; Director, Breast Medical Oncology, Seattle Cancer Care Alliance
Oncology
Julie R. Gralow, MD practices Oncology. He researched medicine at Keck School of Medicine of USC. Keck School of Medicine of USC is ranked 31/72 in Research/PrimaryCare. He over the years received 21 awards: "America's Top Doctors", "America's Top Doctors for Cancer", "Fellow (FASCO)", "American Society of Clinical Oncology Statesman Award", "University of Washington Medical Center Service Excellence Award", "Finding Your Way To Wellness", "Women of Valor", "Above and Beyond", "Susan G. Komen for the Cure, Puget Sound Affiliate, C.J. Taylor Outstanding Community Volunteer Award", "University of Washington Continuing Medical Education Department Outstanding Faculty Award", "Coping Magazine Honorary Hero", "American Cancer Society Clinical Career Development Award", "American Society of Clinical Oncology Career Development Award", "Upjohn Outstanding Oncology Fellow Award", "Janet M. Glasgow/American Medical Women's Association Achievement Award", "U.S.C. School of Medicine Dean's List", "Irving I. Lasky Award for Medical Student Research", "Alpha Omega Alpha Honor Medical Society", "U.S.C. Summer Research Fellowship Award", "Whos Who in Medicine and Healthcare" and "Super Doctor". Doctor Julie R. Gralow, MD is a published doctor and has 70 publications published. The lastest was: 'Screening MRI in Women With a Personal History of Breast Cancer.' Julie R. Gralow is registered with Medicare.
Publications
- Screening MRI in Women With a Personal History of Breast Cancer.
- Optimisation of the continuum of supportive and palliative care for patients with breast Cancer in low-income and middle-income countries: executive summary of the Bre...
- Goserelin for ovarian protection during breast-Cancer adjuvant chemotherapy.
- SWOG S0221: A Phase III Trial Comparing Chemotherapy Schedules in High-Risk Early-Stage Breast Cancer.
- Metabolic syndrome and outcomes following early-stage breast Cancer.
- Tumor Marker Usage and Medical Care Costs Among Older Early-Stage Breast Cancer Survivors.
- Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 ...
- Chemotherapy and Targeted Therapy for Women With Human Epidermal Growth Factor Receptor 2-Negative (or unknown) Advanced Breast Cancer: American Society of Clinical On...
- Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100.
- EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial.
- Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2-negative breast Cancer.
- Adherence to oral diabetes medications and glycemic control during and following breast Cancer treatment.
- Circulating Tumor Cells and Response to Chemotherapy in Metastatic Breast Cancer: SWOG S0500.
- Promoting Quality and Evidence-Based Care in Early-Stage Breast Cancer Follow-up.
- Factors associated with long-term adherence to annual surveillance mammography among breast Cancer survivors.
- A phase II study of docetaxel and vinorelbine plus filgrastim for HER-2 negative, stage IV breast Cancer: SWOG S0102.
- Supportive care after curative treatment for breast Cancer (survivorship care): Resource allocations in low- and middle-income countries. A Breast Health Global Initia...
- Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast Cancer.
- Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2-positive breast Cancer receiving chemotherapy with or without trastuzumab: Results...
- Impact of c-MYC Protein Expression on Outcome of Patients with Early-Stage HER2+ Breast Cancer Treated with Adjuvant Trastuzumab NCCTG (Alliance) N9831.
- Structural and functional studies on the interaction of adenovirus fiber knob domains and desmoglein 2.
- Frequent Antibiotic Use and Second Breast Cancer Events.
- Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast Cancer in the North Cent...
- Is a comparative clinical trial for breast Cancer tumor markers to monitor disease recurrence warranted? A value of information analysis.
- Course of depression, mental health service utilization and treatment preferences in women receiving chemotherapy for breast Cancer.
- Value-of-Information Analysis within a Stakeholder-Driven Research Prioritization Process in a US Setting: An Application in Cancer Genomics.
- Supplement use during an intergroup clinical trial for breast Cancer (S0221).
- Prognostic and Predictive Value of Tumor Vascular Endothelial Growth Factor Gene Amplification in Metastatic Breast Cancer Treated with Paclitaxel with and without Bev...
- The importance of survivors and partners in improving breast Cancer outcomes in Uganda.
- Can bone-targeted therapy reduce recurrence and improve survival in early-stage breast Cancer?
- Hypnosis for Symptom Management in WomenWith Breast Cancer: A Pilot Study.
- Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast Cancer.
- Can We Predict Who's at Risk for Developing Bone Metastases in Breast Cancer?
- How Do We Define Efficacy in Comparing Osteoclast-Targeted Agents in Metastatic Breast Cancer?
- SWOG S0215: a phase II study of docetaxel and vinorelbine plus filgrastim with weekly trastuzumab for HER2-positive, stage IV breast Cancer.
- Genetic predictors of taxane-induced neurotoxicity in a SWOG phase III intergroup adjuvant breast Cancer treatment trial (S0221).
- Fluoroestradiol Positron Emission Tomography Reveals Differences in Pharmacodynamics of Aromatase Inhibitors, Tamoxifen, and Fulvestrant in Patients with Metastatic Br...
- PET Tumor Metabolism in Locally Advanced Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy: Value of Static versus Kinetic Measures of Fluorodeoxyglucose Uptake.
- Phase III comparison of standard doxorubicin and cyclophosphamide versus weekly doxorubicin and daily Oral cyclophosphamide plus granulocyte colony-stimulating factor ...
- C-MYC alterations and association with patient outcome in early-stage HER2-positive breast Cancer from the north central Cancer treatment group N9831 adjuvant trastuzu...
- Proceedings of the First Global Workshop on Breast Cancer: pathways to the evaluation and clinical development of novel agents for breast Cancer.
- Bisphosphonate risks and benefits: finding a balance.
- HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial.
- Pain in long-term breast Cancer survivors: frequency, severity, and impact.
- Tumor metabolism and blood flow as assessed by positron emission tomography varies by tumor subtype in locally advanced breast Cancer.
- Are bisphosphonates ready for the adjuvant setting?
- Kinetic analysis of 18F-fluoride PET images of breast Cancer bone metastases.
- Neoadjuvant chemotherapy for locally advanced breast Cancer.
- NCCN Task Force Report: Bone Health in Cancer Care.
- Randomized phase II trial of denosumab in patients with bone metastases from prostate Cancer, breast Cancer, or other neoplasms after intravenous bisphosphonates.
- Clinical Cancer advances 2008: major research advances in Cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.
- Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced br...
- Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuva...
- Preoperative therapy in invasive breast Cancer: reviewing the state of the science and exploring new research directions.
- Preoperative therapy in invasive breast Cancer: pathologic assessment and systemic therapy issues in operable disease.
- Recruiting patients with breast Cancer and their families to behavioral research in the post-HIPAA period.
- Bone density in breast Cancer: when to intervene?
- Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast Cancer.
- Residual tumor uptake of [99mTc]-sestamibi after neoadjuvant chemotherapy for locally advanced breast Carcinoma predicts survival.
- Sequencing of tamoxifen and radiotherapy after breast-conserving surgery in early-stage breast Cancer.
- Evaluation of the internal mammary lymph nodes by FDG-PET in locally advanced breast Cancer (LABC).
- HER-2 testing in breast Cancer using parallel tissue-based methods.
- Changes in blood flow and metabolism in locally advanced breast Cancer treated with neoadjuvant chemotherapy.
- Overview of Breast health care guidelines for countries with limited resources.
- Myalgias and arthralgias associated with paclitaxel.
- Dose-dense anthracycline-based chemotherapy for node-positive breast Cancer.
- Use of serial FDG PET to measure the response of bone-dominant breast Cancer to therapy.
- Blood flow and metabolism in locally advanced breast Cancer: relationship to response to therapy.
- Detection of locoregional and distant recurrences in breast Cancer patients by using FDG PET.
Schools
University of Southern California Keck School of Medicine
Brigham and Women39s Hospital
University of Washington
Procedures Preformed
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
- Choice Plus POS II
- Blue Card PPO
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Commercial Insurance Company
- First Choice Health PPO
- Coop Core
- Medicare Advantage PFFS
- Medicaid
- Medicare MCR
- Molina
- MultiPlan PPO
- ODS Health Plan
- PacificSource
- Principal Life
- Personal Option EPO
- Preferred Provider Network PPN
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
Awards
- America's Top Doctors
- America's Top Doctors for Cancer
- Fellow (FASCO)
- American Society of Clinical Oncology Statesman Award
- University of Washington Medical Center Service Excellence Award
- Finding Your Way To Wellness
- Women of Valor
- Above and Beyond
- Susan G. Komen for the Cure, Puget Sound Affiliate, C.J. Taylor Outstanding Community Volunteer Award
- University of Washington Continuing Medical Education Department Outstanding Faculty Award
- Coping Magazine Honorary Hero
- American Cancer Society Clinical Career Development Award
- American Society of Clinical Oncology Career Development Award
- Upjohn Outstanding Oncology Fellow Award
- Janet M. Glasgow/American Medical Women's Association Achievement Award
- U.S.C. School of Medicine Dean's List
- Irving I. Lasky Award for Medical Student Research
- Alpha Omega Alpha Honor Medical Society
- U.S.C. Summer Research Fellowship Award
- Whos Who in Medicine and Healthcare
- Super Doctor
Education
-
University of Washington
-
Brigham and Women's Hospital
-
Keck School of Medicine of USC
-
Stanford University
Hospital
-
Seattle Children's Hospital
-
University of Washington Medical Center
Drug Facts
| NPI NUMBER |
|
1144300146 |
| NPPES Provider LastName |
|
GRALOW |
| NPPES Provider FirstName |
|
JULIE |
| NPPES Provider ZIPCode |
|
98109 |
| NPPES Provider State |
|
WA |
| Specialty Description |
|
Medical Oncology |
| Total Claim Count |
|
139.0 |
| Distinct Opioid Count |
|
0.0 |
| Opioid Claim Count |
|
0.0 |
| Percent Opioid Claims |
|
0.0 |
Helpful Reviews
Give
Anonymous Review
Medicare Facts
| National Provider Identifier [NPI] |
1144300146 |
| Last Name Of The Provider |
GRALOW |
| First Name Of The Provider |
JULIE |
| View All |
|
Similar Doctors
Doctor Directory | TOS | twitter | FB | Angel | blog
This Doctor is OpenDoctor Recommended.
This doctor has more publications
